Table 2.
< 15 weeks follow-upa | 15–52 weeks follow-upa | > 52 weeks follow-upa | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
β | p value | SE | 95% CI | β | p value | SE | 95% CI | β | p value | SE | 95% CI | |
Model 1 | ||||||||||||
Dose equivalent/kg | 0.27 | < 0.001 | 0.06 | 0.16 to 0.38 | 0.55 | 0.316 | 0.05 | − 0.05 to 0.16 | − 0.05 | 0.307 | 0.05 | − 0.14 to 0.04 |
Duration of use (weeks) | 0.03 | < 0.001 | 0.00 | 0.03 to 0.04 | 0.01 | 0.088 | 0.00 | 0.00 to 0.02 | 0.00 | < 0.001 | 0.00 | 0.00 to 0.00 |
Baseline BMI z score | 0.92 | < 0.001 | 0.02 | 0.90 to 0.96 | 0.80 | < 0.001 | 0.05 | 0.7 to 0.9 | 0.69 | < 0.001 | 0.07 | 0.56 to 0.83 |
Age (years) | 0.00 | 0.661 | 0.00 | 0.00 to 0.00 | 0.00 | 0.507 | 0.00 | 0.00 to 0.00 | 0.00 | 0.457 | 0.00 | 0.00 to 0.00 |
Sex (male) | 0.10 | 0.076 | 0.06 | − 0.01 to 0.22 | 0.27 | 0.096 | 0.16 | − 0.05to 0.60 | 0.22 | 0.328 | 0.22 | − 0.22 to 0.66 |
Antipsychotic | ||||||||||||
Risperidone | 0.07 | 0.197 | 0.05 | − 0.04 to 0.18 | 0.16 | 0.309 | 0.15 | − 0.14 to 0.45 | − 0.07 | 0.756 | 0.22 | − 0.50 to 0.36 |
Aripiprazole | − 0.03 | 0.401 | 0.07 | − 0.17 to 0.12 | 0.05 | 0.814 | 0.20 | − 0.35 to 0.45 | 0.16 | 0.950 | 0.26 | − 0.49 to 0.52 |
Pipamperone | − 0.07 | 0.255 | 0.06 | − 0.19 to 0.05 | − 0.26 | 0.155 | 0.18 | − 0.61 to 0.10 | 0.08 | 0.762 | 0.26 | − 0.43 to 0.59 |
No previous antipsych. treatment | 0.11 | 0.026 | 0.05 | 0.01 to 0.21 | 0.16 | 0.273 | 0.14 | − 0.12 to 0.43 | 0.13 | 0.524 | 0.20 | − 0.27 to 0.53 |
Psychiatric classification | ||||||||||||
ASS | − 0.01 | 0.913 | 0.07 | − 0.15 to 0.14 | 0.06 | 0.804 | 0.23 | − 0.39 to 0.50 | 0.27 | 0.328 | 0.27 | − 0.27 to 0.80 |
ADHD | − 0.01 | 0.786 | 0.05 | − 0.12 to 0.09 | 0.02 | 0.905 | 0.15 | − 0.27 to 0.31 | 0.23 | 0.249 | 0.20 | − 0.16 to 0.62 |
Other psychiatric class | 0.03 | 0.596 | 0.05 | − 0.08 to 0.14 | − 0.15 | 0.339 | 0.15 | − 0.45 to 0.15 | − 0.10 | 0.630 | 0.20 | − 0.49 to 0.29 |
Somatic diagnosis | ||||||||||||
Epilepsy | − 0.10 | 0.318 | 0.10 | − 0.29 to 0.09 | − 0.16 | 0.534 | 0.26 | − 0.66 to 0.34 | − 0.48 | 0.115 | 0.31 | − 1.08 to 0.12 |
Other | − 0.05 | 0.325 | 0.05 | − 0.15 to 0.05 | − 0.01 | 0.924 | 0.14 | − 0.28 to 0.26 | 0.16 | 0.412 | 0.19 | − 0.21 to 0.53 |
Concomitant medication | ||||||||||||
No stimulant | 0.13 | 0.040 | 0.06 | 0.00 to 0.25 | 0.38 | 0.007 | 0.14 | − 0.11 to 0.66 | 0.43 | < 0.001 | 0.10 | 0.24 to 0.62 |
No other medication | 0.09 | 0.267 | 0.08 | − 0.07 to 0.25 | 0.12 | 0.543 | 0.22 | − 0.31 to 0.55 | 0.01 | 0.948 | 0.16 | − 0.30 to 0.32 |
Ethnicity (Dutch) | − 0.04 | 0.709 | 0.06 | − 0.16 to 0.08 | 0.03 | 0.842 | 0.16 | − 0.29 to 0.35 | 0.27 | 0.285 | 0.25 | − 0.24 to 0.79 |
Sport | − 0.05 | 0.310 | 0.05 | − 0.15 to 0.05 | 0.01 | 0.949 | 0.15 | − 0.28 to 0.30 | − 0.10 | 0.616 | 0.20 | − 0.48 to 0.29 |
IQ < 70 | 0.01 | 0.829 | 0.06 | − 0.10 to 0.12 | 0.04 | 0.779 | 0.14 | − 0.24 to 0.32 | − 0.22 | 0.261 | 0.20 | − 0.61 to 0.16 |
Model 2 | ||||||||||||
Dose equivalent/kg | − 0.05 | 0.518 | 0.08 | − 0.21 to 0.11 | 0.01 | 0.947 | 0.17 | − 0.31 to 0.34 | − 0.08 | 0.079 | 0.05 | − 0.17 to 0.01 |
× Duration of use (weeks) | 0.02 | 0.011 | 0.01 | 0.01 − 0.04 | 0.00 | 0.792 | 0.00 | − 0.01 to 0.01 | 0.00 | 0.880 | 0.00 | 0.00 to 0.00 |
Baseline BMI z score | 1.00 | < 0.001 | 0.02 | 0.96 − 1.04 | 0.85 | < 0.001 | 0.11 | 0.63 to 1.06 | 0.68 | < 0.001 | 0.07 | 0.53 to 0.82 |
× Duration of use (weeks) | − 0.01 | < 0.001 | 0.00 | − 0.02 to 0.01 | 0.00 | 0.667 | 0.00 | − 0.01 to 0.01 | 0.00 | 0.695 | 0.00 | 0.00 to 0.00 |
Sex (male) | 0.07 | 0.284 | 0.07 | − 0.06 − 0.2 | 0.16 | 0.695 | 0.40 | − 0.63 to 0.94 | 0.29 | 0.221 | 0.24 | − 0.17 to 0.75 |
× Duration of use (weeks) | 0.01 | 0.264 | 0.01 | − 0.01 to 0.02 | 0.00 | 0.04 | 0.01 | − 0.02 to 0.03 | 0.00 | 0.623 | 0.00 | 0.00 to 0.00 |
No previous antipsych. Drug | 0.02 | 0.688 | 0.06 | − 0.09 to 1.14 | 0.10 | 0.31 | 0.746 | − 0.5 to 0.7 | 0.23 | 0.262 | 0.21 | − 0.17 to 0.64 |
× Duration of use (weeks) | 0.02 | 0.018 | 0.01 | 0.00 to 0.03 | 0.00 | 0.859 | 0.01 | − 0.02 to 0.02 | 0.00 | 0.141 | 0.00 | 0.00 to 0.00 |
No stimulant | 0.16 | 0.033 | 0.07 | 0.01 to 0.30 | 0.49 | 0.114 | 0.31 | − 0.12 to 1.10 | 0.17 | 0.259 | 0.15 | − 0.13 to 0.48 |
× Duration of use (weeks) | 0.00 | 0.915 | 0.00 | − 0.02 to 0.02 | 0.00 | 0.722 | 0.01 | − 0.02 to 0.02 | 0.00 | 0.201 | 0.00 | 0.00 to 0.00 |
Antipsych antipsychotic, Class classification, SE standard error, 95% CI 95% confidence interval
a < 15 weeks: n = 144 patients, 15–52 weeks 111 patients, > 52 weeks: 58 patients